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Abstract  
 
Nitrazolam and clonazolam are two designer benzodiazepines that are available from 
internet retailers and there is growing evidence suggesting that such compounds 
have the potential to cause severe adverse events. Information about tolerability in 
humans is scarce but typically, low doses can be difficult to administer for users 
when handling bulk material and variability of the active ingredient in tablet 
formulations can also be of a concern. Customs, toxicology and forensic laboratories 
are increasingly encountering designer benzodiazepines, both in tablet and 
powdered forms, and the unavailability of reference standards can impact on the 
ability to identify these compounds. Therefore, the need arises for exploring in-house 
approaches to the preparation of NPS that can be carried out in a timely manner. The 
present study was triggered when samples of clonazolam were received in powdered 
and tablet form at a time when reference material for this drug was commercially 
unavailable. Therefore, microscale syntheses of clonazolam and its deschloro 
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analogue nitrazolam were developed utilizing polymer supported-reagents starting 
from 2-amino-5-chlorobenzophenone (clonazolam) and 2-amino-5-
nitrobenzophenone (nitrazolam). The final reaction step forming the 1,2,4-triazole 
ring moiety was performed within the GC-MS injector. A comparison with a 
preparative scale synthesis of both benzodiazepine derivatives showed that 
microscale synthesis might be an attractive option for a forensic laboratory in terms 
of time and cost savings when compared with traditional methods of synthesis and 
when qualitative identifications are needed to direct forensic casework.  The reaction 
by-product profiles for both the micro and preparative scale syntheses are also 
presented.  
 
 
1 INTRODUCTION  
 
There is growing evidence to show that the so-called designer benzodiazepines,1 i.e. 
derivatives commonly obtained from the patent literature for sale and  large-scale 
synthesis and without a published history of undergoing safety assessments in 
humans, have the potential to cause severe adverse effects.2-7 Customs and forensic 
laboratories are increasingly encountering these substances in both tablet and 
powdered forms. Two examples of recently emerging benzodiazepine derivatives 
include nitrazolam and clonazolam (Figure 1).  
The detection of these drugs and the provision of analytical data has been reported 
by various sources, such as the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) via the European Union early warning system (EWS),8 the 
WEDINOS drug information website,9 the European Response Project,10,11 and the 
Drug Enforcement Administration (DEA) Special Testing and Research Laboratory in 
the United States of America.12 
The preparations of nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-
a][1,4]benzodiazepine) and clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4H-
[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) have been published.13 They have been 
sold online and it appears that their effects might be comparable to other triazolo-
benzodiazepines.14,15 However, it appears that nitrazolam may be less potent than 
clonazolam and triazolam. Studies in animals have shown that nitrazolam can be 
several times more effective than diazepam as an antagonist of electroshock–
induced tonic extensor convulsions.13 Clonazolam has also been sold as an 
uncontrolled drug and, due to its high potency, is believed to cause powerful sedation 
and amnesia at total oral doses of 0.5 mg (typically one tablet).13,16-19 Low doses 
such as this can be complicated to administer for users when handling bulk materials 
and variability of the active ingredient in the tablet are also a concern, where both the 
effects and unintended overdosing raise concerns about incidences of drug facilitated 
crimes.21  
The unavailability of reference standards often presents difficulties in forensic 
analysis where facile and effective approaches are needed to accelerate the 
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availability of these standards. In this study, a potential solution was sought for 
finding a suitable methodology that would address this requirement. This need arose 
when our laboratories received samples of clonazolam in powdered and tablet form 
at a time when reference material for this drug was commercially unavailable. It was 
first aimed to synthesize this compound on a preparative scale to allow for isolation, 
purification and characterization followed by the development of a microscale 
synthesis without compound isolation whereby the amounts obtained were available 
in sufficient quantity for analysis by gas chromatography mass spectrometry (GC-
MS). In addition, the final reaction step forming the 1,2,4-triazole ring moiety was 
performed within the GC-MS injector to accelerate the procedure (Figure 1). Finally, 
the syntheses procedures carried out both on the preparative and microscale was 
extended to the deschloro analog nitrazolam.   
 
2 EXPERIMENTAL 
 
2.1 Chemicals  
 
A nitrazolam standard, all reagents and solvents used in the syntheses were 
obtained from Sigma Aldrich Ltd (Arklow, Co. Wicklow, Ireland) and Fluorochem Ltd. 
(Hadfield, Derbyshire, UK). LC-MS grade solvents were obtained from Fisher 
Scientific (Dublin, Ireland). Clonazolam containing tablets labeled to contain 0.5 mg 
and pure powder samples were obtained from an Internet retailer. For single crystal 
X-ray diffraction analysis, a portion of the vendor sample of clonazolam was 
recrystallized from ethanol.  
 
2.2 Synthesis 
 
2.2.1 Microscale syntheses of nitrazolam and clonazolam 
 
Micro-reaction vessels (2 mL, clear glass vial, styrene-butadiene septum with solid 
cap, O.D. × H 16 mm × 56 mm; product code 27037; Sigma Aldrich, Arklow, Co. 
Wicklow, Ireland) were used for the reactions. A suitably drilled aluminum block, 
placed on a hotplate-stirrer, was used to perform reactions (see Supporting 
Information 1 for photographs of set-up). The micro-reaction vessels were capped 
during the reactions and mixing was accomplished using PTFE-coated rare earth 
core stir bars. 
 
Step A (Figure 1). A mixture of 2-amino-5-nitrobenzophenone (starting material for 
nitrazolam) or 2-amino-5-chlorobenzophenone (starting material for clonazolam) (10 
mg), 2-chloro-1,1,1-triethoxyethane (20 μL) and glacial acetic acid (10 μL) was 
heated (heating block set at 90 °C) in a reaction vial (2 mL) for 3 h, during which the 
solid dissolved. The mixture was allowed to cool to room temperature and partitioned 
between ethyl acetate (1 mL) and saturated aqueous sodium bicarbonate (1 mL). 
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This was then centrifuged (2,770 g for 3 min). The upper layer was transferred to 
another reaction vial (2 mL) and blown to dryness (air, 35 to 40 °C). 
	
Step B. The residue was dissolved in acetone (500	μL) and sodium iodide (25 mg) 
was added. The mixture was stirred at room temperature for 1.5 h and blown to 
dryness (air, 35 to 40 °C).  
	
Step C. Dichloromethane (1 mL) was added to the residue and the mixture was 
stirred for 5 min. This was then centrifuged (4,000 rpm for 3 min.) and the 
supernatant was transferred to another reaction vial (2 mL). Azide exchange resin 
(50 mg, azide on Amberlite® IRA-400, 3.8 mmol/g, Sigma Aldrich cat. no. 368342) 
was added and the mixture was stirred overnight at room temperature. This was then 
filtered through a plug of cotton wool using a Pasteur pipette (using 0.5 mL 
dichloromethane to rinse the reaction vial). The filtrate was blown to dryness (air, 35 
to 40 °C). 
 
Step D. The residue was dissolved in tetrahydrofuran (490 μL) and water (10 μL). 
Polymer bound triphenylphosphine (50 mg, ~3 mmol/g, Sigma Aldrich cat. no. 93093) 
was added and the mixture was stirred at room temperature for 90 min. This was 
then centrifuged (2,770 g for 3 min.). The supernatant was collected and the residue 
was washed with tetrahydrofuran (1mL).  The supernatant and washing was blown to 
dryness (air, 35 to 40°C). 
 
Step E.  Methanol (150 μL) was added to the residue and the mixture was 
centrifuged (2,770 g for 3 min). The supernatant was transferred to a reaction vial (2 
mL). A solution (50 µL), containing acetylhydrazine (acethydrazide, 90%, 5 mg, 100 
mg/mL) and glacial acetic acid (100 µL/mL) in methanol, was added. The mixture 
was stirred overnight at room temperature and then blown to dryness (air, 35 to 40 
°C). The residue was partitioned between ethyl acetate (1 mL) and saturated 
aqueous sodium bicarbonate (1 mL). This was then centrifuged (2,770 g for 3 min.). 
The upper layer was transferred to another reaction vial (2 mL) and blown to dryness 
(air, 35 to 40 °C).  The residue was taken up in acetonitrile (1 mL) and the solution 
was centrifuged (2,770 g for 3 min). The supernatant was collected and stored in a 
fridge.  
 
Step F. An aliquot of the solution from step (E) (50 μL) was diluted with acetonitrile 
(950 μL) and analyzed by GC-MS. Standards of nitrazolam or clonazolam (50 μg/mL 
in acetonitrile) were also run. 
 
2.2.2 Clonazolam – preparative scale synthesis 
 
5-(2-Chlorophenyl)-2-ethoxy-7-nitro-3H-benzo[e][1,4]diazepine 
 
A mixture of 2-amino-2’-chloro-5-nitrobenzophenone (1.66 g, 6 mmol), 2-chloro-
1,1,1-triethoxyethane (1.38 g, 6.9 mmol), glacial acetic acid (360 μL) and toluene (5 
mL) was refluxed for 6 h. After cooling to room temperature, the mixture was 
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partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The 
organic layer was dried (anhydrous magnesium sulfate) and the volatiles were 
removed to afford a brown oil, which was dissolved in acetone (60 mL). Sodium 
iodide (1.35 g, 9 mmol) was added and the mixture was stirred at room temperature 
for 5 h and then evaporated to dryness. The residue was partitioned between 
dichloromethane and water (containing a small amount of sodium thiosulfate). The 
organic layer was collected and dried (anhydrous magnesium sulfate). Removal of 
the solvent afforded a brown oil (2.62 g). This was dissolved in ethanol (60 mL) and 
sodium azide (780 mg, 12 mmol) was added. The mixture was stirred overnight at 
room temperature and then concentrated to a small volume under vacuum. The 
residue was partitioned between ethyl acetate and water. The organic layer was 
collected and evaporated to afford a brown oil (2.36 g), which was dissolved in 
tetrahydrofuran (30 mL). Water (600 μL) and triphenylphosphine (1.89 g, 2.4 mmol) 
were added and the mixture was stirred overnight at room temperature. The mixture 
was evaporated to dryness to afford a brown oil (3.76 g). A portion of this (960 mg) 
was purified by preparative TLC (silica gel, 2 mm; hexane/ethyl acetate, 7/3) to afford 
a light yellow powder (158 mg): m.pt 119–121 °C; 1H NMR (400, MHz, d6 DMSO) δ 
8.33 (dd; J = 9.0, 2.5 Hz; 1 H; Ar H-5), 7.79 (d; J = 2.5 Hz; 1 H; Ar H-3), 7.67-7.64 
(ddd; J = 7.4, 1.4, 0.4 Hz; 1 H; Ar H-3’) 7.57 – 7.49* (m; 3 H; Ar H-4’, 5’ and  6’), 7.47 
(d; J = 9 Hz; 1 H; Ar H-6), 4.37 (q; J = 7.1 Hz; 2 H; CH2 from ethyl group), 4.17 
(apparent br. s; 2 H; CH2) and 1.31 (t; J = 7.1 Hz; 3 H; CH3) ppm; 
13C NMR (151 
MHz, d6 DMSO) δ 168.01 (CH3-C=N), 161.85 (N=C=O), 151.90 (Ar C-4), 141.35 (Ar 
C-1 or 2), 137.60 (Ar C-1 or 2), 131.81 (Ar C-1’), 131.47 (Ar C-4’, 5’ or 6’), 131.45 (Ar 
C-3’), 129.75 (Ar C-4’, 5’ or 6’), 128.18 (Ar C-2’), 127.89 (Ar C-6), 127.51 (Ar C-4’, 5’ 
or 6’), 125.44 (Ar C-5), 124.26 (Ar C-3), 63.98 (CH2 from ethyl group), 52.48 (CH2) 
and 13.75 (CH3) ppm (* 7.57-7.53 ppm – partial resolution into a dd and tr indicating 
Ar H-6- and Ar H-4’/5’); HRMS found, 344.0792 [M+H]+, C17H15
35ClN3O3 , requires 
344.0796 (Δ = 1.4 ppm). 
 
6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine 
(clonazolam)  
 
A solution of 5-(2-chlorophenyl)-2-ethoxy-7-nitro-3H-benzo[e][1,4]diazepine (100 mg, 
0.29 mmol), acetylhydrazine (acethydrazide, 90%,  29 mg, 0.35 mmol) and glacial 
acetic acid (18 μL) in methanol (3 mL) was stirred for 48 h at room temperature. The 
volatiles were removed under vacuum and the residue was triturated with tert-butyl 
methyl ether to afford a yellow powder (99 mg). This was heated (sand bath at 225 
°C) for 10 min under reduced pressure to afford yellow powder. This was purified by 
preparative TLC (silica gel, 2 mm; ethyl acetate/methanol, 9/1) and triturated with 
tert-butyl methyl ether to afford an almost colorless solid (50 mg, 0.14 mmol, 48%) 
m.pt 231-233 °C (lit. 229-231 ºC13); 1H NMR (400 MHz, d6 DMSO) δ 8.55 (dd; J = 
8.9, 2.6 Hz;  1 H; Ar H-5), 8.15 (d; J = 8.9 Hz; 1 H; Ar H-6), 7.87 (d; J = 2.6 Hz; 1 H; 
Ar H-3), 7.74-7.70 (m; 1 H; Ar H-3’), 7.57 – 7.52 (m; 2 H; Ar H-4’ and  5’), 7.50 – 7.46 
(m; 1 H; Ar H-6’), 5.31 (d; J = 13.2 Hz; 1 H; one H from CH2), 4.35 (d; J = 13.2 Hz; 1 
H; one H from CH2), 2.59 (s;  3 H; CH3). ppm; 
13C NMR (101 MHz, d6 DMSO) δ 
166.53 (Ar-C=N), 154.25 (CH2-C=N), 150.66 (CH3-C=N), 145.40 (Ar C-4), 137.72 (Ar 
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C-1 or 2), 137.38 (Ar C-1 or 2), 131.74 (Ar C-4’ or 5’), 131.23 (Ar C-3’ overlapped 
with Ar C- 1’ or 2’), 130.30 (Ar C-1’or 2’), 129.82 (Ar C-6’), 127.63 (Ar C-4’ or 5’), 
126.51 (Ar C-5), 125.77 (Ar C-6), 124.35 (Ar C-3), 45.80 (CH2), 11.62 (CH3) ppm; 
HRMS found, 354.0750 [M+H]+, C17H13
35ClN5O2, requires 354.0752 (Δ = 0.6 ppm). 
 
2.2.3 Nitrazolam  – preparative scale synthesis 
 
2-Ethoxy-7-nitro-5-phenyl-3H-benzo[e][1,4]diazepine 
 
A mixture of 2-amino-5-nitrobenzophenone (484 mg, 2 mmol), 2-chloro-1,1,1-
triethoxyethane (460 mg, 2.3 mmol), glacial acetic acid (120 μL) and toluene was 
refluxed for 5 h.  After cooling to room temperature, the mixture was partitioned 
between ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer 
was dried (anhydrous magnesium sulfate) and the volatiles were removed to afford a 
yellow oil (697 mg). This was dissolved in acetone (20 mL) and sodium iodide (450 
mg, 3 mmol) was added. The mixture was stirred at room temperature for 3 hr. and 
then evaporated to dryness. The residue was partitioned between dichloromethane 
and water (containing a small amount of sodium thiosulfate), the organic layer was 
collected and dried (anhydrous magnesium sulfate). Removal of the solvent afforded 
a viscous brown oil. This was dissolved in ethanol (20 mL) and sodium azide (260 
mg, 4 mmol) was added. The mixture was stirred overnight at room temperature and 
then concentrated to a small volume (2 mL) under vacuum. The residue was 
partitioned between ethyl acetate and water.  The organic layer was collected and 
evaporated to afford a brown oil (601 mg). This was dissolved in tetrahydrofuran (10 
mL). Water (200 μL) and triphenylphosphine (630 mg, 2.4 mmol) were added and the 
mixture was stirred overnight at room temperature. The mixture was evaporated to 
dryness and the residue was purified by preparative TLC (silica gel, 2 mm; 
hexane/ethyl acetate, 8/2) to afford a yellow solid (299 mg, 0.97 mmol, 48 %): m.pt 
136–138 °C (lit. 143-145 ºC20); 1H NMR (400, MHz, d6 DMSO) δ 8.36 (dd; J = 9.0, 2.7 
Hz; 1 H; Ar H-5), 8.06 (d; J = 2.7 Hz; 1 H; Ar H-3), 7.58 – 7.52 (m; 3 H; Ar H-2’, 4’ 
and 6’), 7.50- 7.44 (m; 3 H; Ar H-3’, 5’ and 6), 4.32 (m; 2 H; CH2 from ethyl group) 
and 1.30 (t; J = 7.1 Hz; 3 H; CH3) ppm*; 
13C NMR (151 MHz, d6 DMSO) δ 168.43 
(CH3-C=N), 163.01(N=C=O), 153.10 (Ar C-4), 141.13 (Ar C-1 or 1’), 138.03 (Ar C-1 
or 1’), 130.61 (Ar C-4’), 129.56 (Ar C-2’ and 6’), 128.44 (Ar C-3’ and 5’), 127.54 (Ar 
C-6), 127.23 (Ar C-2), 126.08 (Ar C-3), 125.40 (Ar C-5), 63.85 (CH2), 52.39 (CH2) 
and 13.78 (CH3) ppm; APCI HRMS found 310.1198, [M+H]
+, C17H16N3O3, requires 
310.1186 (Δ = -3.9 ppm).  
* The diazepine ring CH2 was not observed as a sharp identifiable signal in the 
1H 
NMR spectrum (Supporting Information 2). A broad signal from 3.5 to 5 ppm may 
account for this. In the HSQC experiment, this CH2 peak in the 
13C spectrum had no 
discernible connectivity to a signal in the 1H spectrum (Supporting Information 2), 
which may be due to the rapid interconversion of diazepine ring conformers. 
 
1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (nitrazolam)  
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A solution of 2-ethoxy-7-nitro-5-phenyl-3H-benzo[e][1,4]diazepine (247 mg, 0.80 
mmol), acetylhydrazine (acethydrazide, 90%,  67 mg, 0.81 mmol) and glacial acetic 
acid (50 μL) in methanol (10 mL) was stirred overnight at room temperature. The 
mixture was then evaporated to dryness, and the residue was triturated with tert-butyl 
methyl ether and then filtered to afford a yellow powder (222 mg). A portion (52 mg, 
0.15 mmol) of this was heated (sand bath at 225 °C), under reduced pressure for 10 
min. The resulting brown material (45 mg) was triturated with ethyl acetate and tert-
butyl methyl ether to afford a light beige powder (30 mg): m.pt 228–230 °C (from 
ethyl acetate, lit. 231.5-232.5 ºC13); 1H NMR (600 MHz, d6 DMSO) δ 8.58 (dd; J = 
9.0, 2.6 Hz; 1 H; Ar H-5), 8.10 (d; J = 9 Hz; 1 H; Ar H-6) 8.09 (d; J = 2.7 Hz; 1 H; Ar 
H-3), 7.62-7.58 (m; 2 H; Ar H-2’ and 6’), 7.54 (dist. tr; J = 7.3 Hz; 1 H; Ar H-4’), 7.47-
7.42 (m; 2 H; Ar H-3’ and 5’), 5.28 (d; J = 13.0 Hz; 1 H; one H from CH2), 4.25 (d; J = 
13.0 Hz; 1 H; one H from CH2) and 2.63 (s; 3 H; CH3) ppm; 
13C NMR (151 MHz, d6 
DMSO) δ 167.28 (Ar-C=N), 154.37 (CH2-C=N), 150.79 (CH3-C=N), 144.99 (Ar C-4), 
138.37 (Ar C-1 or 1’), 138.24 (Ar C-1 or 1’), 130.81 (Ar C-4’), 129.37 (Ar C-2’ and 6’), 
129.35 (Ar C-2) 128.27 (Ar C-3’ and 5’), 126.36 (Ar C-3 or 6), 126.24 (Ar C-5), 
125.70 (Ar C-3 or 6), 45.70 (CH2) and 11.76 (CH3) ppm; APCI HRMS found 
320.1141, [M+H]+, C17H14N5O3, requires 320.1142 (Δ = -0.3ppm).  
 
2.3 Analysis of clonazolam tablets 
2.3.1 Quantification of clonazolam in tablets by Liquid chromatography-low 
resolution mass spectrometry (LC-LRMS) 
 
A crushed tablet was extracted with acetonitrile (2 x 2 mL, 5 min. sonication). The 
combined supernatants were subjected to centrifugation (1,550 g for 5 min), made up 
to 5 mL with acetonitrile (solution A). Water (500 µL, containing 0.01% formic acid) 
was added to solution A (500 µL) and the mixture was filtered through a 0.2 µm nylon 
filter, Costar Spin-X). The filtrate (200 µL) was diluted with acetonitrile/water (600 µL, 
containing 0.05 % formic acid) and this was analysed using liquid chromatography-
low resolution mass spectrometry (LC-LRMS) as detailed below. A series of 
clonazolam standards (6.25, 12.5, 25, 50, 100, 200 µg/mL) were prepared in 
acetonitrile/water (containing 0.05 % formic acid) and analysed along with the 
sample. 
 
2.3.2 Sample preparation for the identification of clonazolam in tablets by 60 
MHz (bench-top) NMR. 
 
Two tablets were crushed together and the powder was extracted with CDCl3 (0.70 
mL) by rolling for 10 min. The mixture was the centrifuged at 20,000 g for 5 min and 
the supernatant was analysed by 60 MHz benchtop NMR as detailed below. 
 
2.4 Instrumentation 
 
2.4.1 Gas chromatography-mass spectrometry (GC-MS) 
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Samples were analyzed on an Agilent 6890N gas chromatograph coupled to a 5975 
insert MSD. A HP ULTRA 1 column (12 m × 0.2 mm × 0.33 μm) was used in split 
mode (1:1 or as stated) with helium carrier gas at a constant flow of 0.8 mL/min. The 
injection port and transfer line temperatures were set at 250 °C and 280 °C 
respectively. The initial oven temperature was 60 °C, held for 2 min and then ramped 
at 25 °C/min to 295 °C with a final hold time of 5.6 min (total run time 17 min). The 
ionization energy was set at 70 eV, the quadrupole at 150 °C, the ion source at 
230 °C and the mass range was set at m/z 40–550. 
 
2.4.2 High-resolution atmospheric pressure chemical ionization (APCI) 
electrospray ionization (ESI) mass spectrometry for the determination of 
elemental composition 
 
High-resolution mass spectra (HRMS) for verification of elemental composition were 
recorded on a Bruker micrOTOF-Q III spectrometer interfaced to a Dionex UltiMate 
3000 LC for sample injection. They system has a mass resolution 20,000 (FWHM) at 
LC-speed and mass accuracy 1 - 2 ppm RMS error. Agilent Tune Mix-L was used for 
calibration. HyStar 3.2 and Data Analysis 4.1 were utilized for system control and 
data processing. Both electrospray ionisation (ESI) and atmospheric pressure 
chemical ionisation (APCI) sources were used to carry out analysis as necessary, 
with the following conditions: 
 
ESI experiments were recorded over the range 50-2000 m/z, end-plate offset 500 V 
capillary 4500 V, nebulizer 2.0 Bar, dry gas 8.0 L/min, and dry temperature 180°C.  
 
APCI experiments were recorded over a range of 50-1600 m/z, capillary voltage 
4000 V, corona 4000 nA, nebulizer gas 2.0 Bar, dry gas 3.0 L/min, dry gas 
temperature 200°C, vaporiser temperature 400°C. 
 
2.4.3 Liquid chromatography-low resolution mass spectrometry (LC-LRMS) 
This was used for the quantification of clonazolam in the tablets and to obtain product 
ions spectra for clonazolam and nitrazolam utilizing in-source CID. 
 
Analyses were performed on an Agilent 1100 HPLC system equipped with a G13795 
degasser, G1312A BinPump, a G1313A ALS and G1316A column oven (COLCOM) 
(Agilent, Little Island, Cork). Separation was obtained on an Allure PFP Propyl 
column (5 μm, 50 x 2.1 mm) Restek (Bellefonte, PA, USA). Mobile phase A consisted 
of 0.1% formic acid in water, whereas mobile phase B consisted of 0.1% formic acid 
in acetonitrile. The flow rate was set at 0.80 mL/min, with an injection volume of 10 
µL, and the column temperature was 30°C. The following gradient elution program 
was used: 0-2 min 2% B, followed by an increase to 60% B within 15 min, followed 
by another increase to 80% B within 18 min before returning to 2% B within 25 min 
(total run time was 25 min.). The Agilent LC-MSD mass spectrometer settings were 
as follows: positive electrospray mode, capillary voltage 3500 V, drying gas (N2) 12 
L/min at 350 °C, nebulizer gas (N2) pressure 50 psi, and scan mode m/z 70–500. 
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To obtain product ions spectra, samples were dissolved in acetonitrile/water (1:1, 
containing 0.1% formic acid) and the fragmentor voltage was set at 150 V. For the 
quantification of clonazolam in tablets, the fragmentor voltage was set at 50 V. 
 
2.4.4 Nuclear magnetic resonance (NMR) spectroscopy 
 
The following instruments were used to acquire NMR spectra. Spectra are shown in 
Supporting information 3. 
 
Instrument 1: 1H (600 MHz) and 13C (150 MHz, referenced to the NMR solvent peak) 
spectra were recorded on a Bruker AV600 NMR spectrometer, in the solvent stated, 
using a 5 mm TCI cryoprobe. 1H NMR spectra were referenced to an external TMS 
reference at δ = 0 ppm.  
 
Instrument 2: 1H NMR (400 MHz), and 13C NMR (100 MHz) spectra were recorded on 
a Bruker Avance III 400 MHz spectrometer performed at 293K in the solvent stated. 
Chemical shifts (δ) are given in parts per million (ppm) where TMS singlet is set at 0 
ppm. Coupling constants are given as absolute values in Hertz. 
 
Instrument 3: The 1H (60 MHz)	spectrum was recorded on a NMReady-60e benchtop 
NMR spectrometer (Nanalysis Corp, Calgary, Canada) using the following conditions: 
5 mm NMR tube; 4096 scans at 32°C; pulse sequence, 1DPULSEACQUIRE. Data 
was processed in MNova 12.0 (Mestrelab Research, Santiago de Compostela, 
Spain). 
 
 
 
2.4.5 X-Ray crystallography for clonazolam 
 
Data (Supporting Inofrmation 4) were measured on a Bruker D8 Quest Eco 
diffractometer at 100 K using an Oxford Cryostream with the sample mounted on a 
MiTeGen microloop using Mo Kα radiation (λ = 0.71073Å). Bruker APEX software 
was used to collect and reduce data and determine the space group.22 Absorption 
corrections were applied using SADABS.23 The structure was solved with the XT 
structure solution program using Intrinsic Phasing and refined with the XL refinement 
package using Least Squares minimisation in Olex2.24-26 All non-hydrogen atoms 
were refined anisotropically. Hydrogen atoms were assigned to calculated positions 
using a riding model with appropriately fixed isotropic thermal parameters Crystal 
data, details of data collections and refinement are given below. CCDC 1569730 
contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre.27  
 
Crystal Data for C17H12ClN5O2 (M =353.77 g/mol): monoclinic, space group P21/n (no. 
14), a = 8.3378(5) Å, b = 13.1153(8) Å, c = 14.7638(9) Å, β = 102.804(2)°, V = 
1574.32(17) Å3, Z = 4, T = 109.99 K, μ(MoKα) = 0.265 mm-1, Dcalc = 1.493 g/cm3, 
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29591 reflections measured (5.66° ≤ 2Θ ≤ 56.846°), 3947 unique (Rint = 0.0284, 
Rsigma = 0.0163) which were used in all calculations. The final R1 was 0.0350 (I > 2σ
(I)) and wR2 was 0.0929 (all data). CCDC 1569730. 
 
 
3 RESULTS AND DISCUSSION 
 
At the time when the powdered and tablet samples believed to contain clonazolam 
were obtained, reference material was not commercially available, which triggered 
the need to confirm the identification by organic synthesis on a preparative scale. 
From the perspective of aiding qualitative identification, it was hypothesized that the 
preparation on a microscale synthesis would generate sufficient amounts of material 
in an accelerated manner suitable for analysis by GC-MS without the need for 
purification. The smaller quantities used for the microscale methodology were 
considered to make it more attractive to a forensic laboratory environment in terms of 
time and cost involved and the organic chemistry manipulation skills required. 
Furthermore, larger volumes of solvents and reagents used in preparative work also 
pose a problem regarding waste disposal and the impact on the environment.  
This investigation describes a novel approach for preparing NPS reference standards 
using a microscale synthesis procedure and polymer-supported reagents. 
Clonazolam and the deschloro analogue nitrazolam were studied as prototypical 
compounds to evaluate this strategy (Figure 1). In addition, both clonazolam and 
nitrazolam were synthesized on a preparative scale using methods that have 
previously been described in the literature.13,14,20,28,29 These are similar to the 
microscale method (Figure 1). The EI mass spectral data (Figure 2) obtained for 
clonazolam and nitrazolam, synthesized on a preparative scale, were found to be in 
good agreement with previously published data.10,11,12,15,16 The quantitative analysis of 
clonazolam tablet samples (reported to contain 0.5 mg), using the synthesized 
material as a reference standard, yielded a value of 0.52 mg clonazolam per tablet 
(Supporting Information 5).  
 
3.1 Microscale synthesis 
Reaction of the benzophenone derivatives (1a/b) with 2-chloro-1,1,1-triethoxyethane, 
followed by the elimination of ethanol, resulted in either (2a) (ethyl (E)-N-(2-benzoyl-
4-nitrophenyl)-2-chloroacetimidate) for nitrazolam or (2b) (ethyl (E)-2-chloro-N-(2-(2-
chlorobenzoyl)-4-nitrophenyl)acetimidate) for clonazolam. Conversion of the chloride 
to an iodide was accomplished using sodium iodide and acetone (Finkelstein 
reaction) to afford (3a/b) (Figure 1). 
       [Insert Figure 1 here] 
In step C, a suspension of polymer-supported azide in dichloromethane was used to 
convert the iodide to the azide (4a/b), which follows a well-established synthetic 
pathway to alkyl azides by nucleophilic substitution.30 It has been reported that 
insoluble polymeric reagents can be used in large excess to complete this conversion 
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into an alkyl azide.31 In step D, the residue was dissolved in tetrahydrofuran/water 
and polymer-supported triphenylphosphine was added to convert the azide to an 
amine which spontaneously lead to ring closure (imine formation) to afford the ethoxy 
benzodiazepine intermediate (5a/b). Polymer-supported triphenylphosphine has 
previously been used for the Staudinger reaction, where the conversion of an 
organoazide (R-N3) by a tertiary phosphine produced an iminophosphorane 
(R3P=NR) that hydrolyzed to give primary amines.
32-34 
	
In step E, acetyl hydrazine, in a mixture of glacial acetic acid and methanol, was 
used to form the acetylhydrazides (6a/b), and the final step (F) was the formation of 
the triazole ring by thermolysis on the GC injector. The solutions of (6a/b) in 
acetonitrile could be stored at 4–8oC but it was found that the benzodiazepine 
derivatives were not produced after several months of storage.  
 
A microscale synthesis approach may help with directing forensic casework, given 
that the approach allows for a fast qualitative identification, thus supporting decision 
making processes. The last reaction, step F, carried out in the microscale synthesis 
required heat supplied by the GC injection port. However, if a standard was required 
for LC analysis, then the same reaction step could be performed in a heated 
microvial.  
 
 
3.2 Microscale and preparative scale synthesis by-products 
 
The microscale synthesis resulted in the formation of by-products (Figure 2 and 
Supporting Information 6). For nitrazolam, the benzophenone starting material (1a) 
and the intermediate (5a) were identified. The O-methoxy analogue of (5a) was also 
tentatively identified, presumably due to methanolysis of (5a) during step E. The by-
product profile suggested incomplete reactions to occur during some steps. The 
yields were considered low and estimated at around 4–15% based on comparison of 
peak areas for a standard and reactions. However, this did not impact on the ability 
to record suitable EI mass spectra, thus allowing for the data to be used for 
qualitative purposes. The microscale syntheses products also afforded acceptable 
chromatographic peaks, regarding retention time and peak shape, when compared 
with the standards synthesized on a preparative scale. (Figure 2). It must be borne in 
mind that a balance must be struck between the expeditious preparations of 
compounds and optimization of yields when a laboratory has a high-throughput of 
samples for forensic analysis. A similar by-product pattern was observed for 
clonazolam. 
 
Analysis of the crude clonazolam and nitrazolam products obtained from the 
preparative scale syntheses by GC-MS and LC-MS, revealed the presence of the 
expected products along with some residual hydrazide starting material (Supporting 
Information 7). A small amount of amino-clonazolam and nitrazolam, where the nitro 
group has been reduced to an amino group, was also observed. Interestingly, the 
thermal decomposition of  nitrazepam and clonazepam, during GCMS analysis, to 
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their corresponding amino analogs has been previously reported.35 In the case of 
clonazolam, the presence of a minor amount of the benzophenone starting material 
was also observed. Overall, the crude product attained from the preparative scale 
products appeared to be 'cleaner’ than the products derived from the microscale 
procedures. Interestingly, none of the reaction by-products observed in the 
preparative scale synthesis were seen in the vendor clonazolam samples (tablets 
and powder). 
 
3.3 Mass spectral characterization and fragmentation pathways for clonazolam 
and nitrazolam  
 
The chromatograms and EI mass spectra for microscale synthesis are shown in 
Figure 2. The chromatographic peaks displayed good symmetry and retention time 
matches with the standards. In Figure 3 (a-c), the proposed EI mass spectral 
fragmentation pathways for nitrazolam and clonazolam are shown. The molecular 
ions of nitrazolam (m/z 319) and clonazolam (m/z 353) (35Cl isotopes) formed 
fragment ions at m/z 302 and m/z 336 respectively, indicating loss of a hydroxyl 
radical. Loss of nitrous acid from the molecular ions was thought to result in the 
formation of m/z 272 (nitrazolam) and m/z 306 (clonazolam). Loss of nitrogen from 
these fragment ions lead to the formation of m/z 244 and m/z 278 (Figure 3a). Loss 
of a hydrogen radical and re-arrangement, with loss of CO, resulted in the formation 
of fragment ions at m/z 290 (nitrazolam) and m/z 324 (clonazolam) (Figure 3b). In the 
case of clonazolam, there was a further loss of a chlorine radical from m/z 324 
yielding the fragment at m/z 290. Other fragment ions formed from the molecular ions 
resulted from contraction of the diazepine ring (Figure 3c).36 The loss of nitrogen and 
propyne, forming the quinazoline radical cation (Q), is suggested to subsequently 
lose hydrogen chloride to yield m/z 249 (clonazolam). This fragment ion Q might also 
be envisioned to also lose nitrous acid with formation of m/z 204 (nitrazolam) and m/z 
238 (clonazolam). The positive ESI product ion mass spectra (150 V in-source CID) 
nitrazolam and clonazolam are shown in Figure 4. Fragments due to ‘loss of 
nitrogen’, [M+H-NO2+O2]
+, afforded m/z 306 (nitrazolam) and m/z 340 (clonazolam). 
This unusual fragmentation behavior, i.e. loss of 14 u from the protonated molecule, 
has been previously reported.37 
 
[Insert Figures 2, 3 and 4 here] 
 
3.4 X-ray crystallography of clonazolam (vendor sample) 
 
Full x-ray crystallography data for the recrystallized (ethanol) clonazolam powder is 
presented in Supporting Information 4. The central ring system is similar in 
conformation and bond lengths/angles to many of the structurally characterized 
alprazolam benzodiazepine derivatives.38-43 An overlay of the x-ray structure with that 
of alprazolam (C2-C22 in 1, hydrogen atoms omitted) yields a RMS deviation of only 
ca. 0.123Å. In 1, the torsion angle between the central seven membered ring and m-
chlorophenyl substituent is 127.828(3) Å (N9-C8-C7-C2). However, despite the nitro 
group and the aromaticity of the compound, there are no strong H-bonding or π-π 
Accepted/uncorrected version – Drug Testing and Analysis (08 March 2018) 
	 13 
interactions. Weak intermolecular interactions include C-Cl…π (ca. 3.45 Å) and 
CH…N π (C4…N13 triazole, ca. 3.5 Å).  
 
3.5 NMR spectra  
NMR spectra, recorded in CDCl3 have previously been reported for clonazolam (7a) 
and nitrazolam (7b).15-16 This data is in good agreement with spectra (d6 DMSO) 
obtained for the preparative scale synthesized clonazepam and nitrazolam here 
(Supporting Information 3). Minor differences in chemical shifts, attributed to solvent 
effects, were noted e.g. the values of 2.59 (clonazolam) and 2.63 (nitrazolam) ppm 
found here for the CH3 group, versus 2.7 and 2.69 respectively for the reported 
values.  A distinctive feature of both 1H spectra is the non-equivalence of the 
hydrogens observed for the diazepine CH2 group which appear in form two doublets 
(4.35/5.31 ppm with J = 13.2 Hz for clonazolam and 4.25/5.28 ppm with J = 13.0 Hz 
for nitrazolam). Published values were noted as 4.20/5.63 ppm (J = 13.1 Hz) and 
4.09/5.56 ppm (J = 14.11 Hz) respectively and these differences were again 
attributed to solvent effects. In the 13C NMR spectrum, the Ar-C=N carbon in the 
diazepine ring is characteristically seen downfield at 166.53 (clonazolam) and 167.28 
(nitrazolam) ppm (published values 167.31 and 167.6 ppm respectively). The 
clonazolam tablets were also analysed by low-field benchtop NMR. In the 60 MHz 1H 
NMR spectrum, recorded using the supernatant obtained by extracting two crushed 
tablets (equivalent to approximately 1 mg clonazolam) with CDCl3, it was possible to 
see several key features (Supporting Information 3). The methyl group was noted at 
2.65 ppm and the diazepine CH2 was observed as a pair of doublets (J = 13.1 Hz) at 
4.14 and 5.59 ppm. Interestingly, it was also possible to distinguish a doublet (8.05 
ppm, J = 2.5 Hz) and double doublet (8.48, J = 9.0, 2.5 Hz), possibly corresponding 
H-3 and H-5 respectively. Overall the data was found to be in good agreement with 
the high-field 1H NMR data published for clonazolam in CDCl3.
16 
 
4 CONCLUSION 
 
The work presented here has shown the usefulness of microscale synthesis for the 
syntheses of two benzodiazepine derivatives of forensic interest. The traditional 
preparative scale synthesis is significantly more complex and the developed 
microscale synthesis approach facilitated a rapid generation of standards useable for 
qualitative identification purposes. From this viewpoint, more approaches are needed 
to develop the in-house expertise of forensic personnel to accelerate the availability 
of reference standards rather than solely relying on external reference standard 
suppliers. This study reflects a proof of concept but the development of a simple 
microscale method, utilizing polymer-supported reagents, has the potential to be 
applicable to a whole range of benzodiazepine derivatives, especially when 
qualitative identifications are needed to direct forensic casework and when reference 
materials are not available. This approach could be used by forensic laboratories to 
shorten the timeframe between the emergence of a new compound on the drugs 
market and the availability of drug standards. 
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Figure 1. Microscale synthetic sequence for nitrazolam (X = H) and clonazolam (X = Cl). 
Reagents used for each step: A. 2-chloro-1,1,1-triethyoxyethane, acetic acid; B. sodium 
iodide, acetone; C. polymer-supported azide, dichloromethane; D. polymer-supported 
triphenylphosphine, tetrahydrofuran, water; E. acetylhyrazine, acetic acid, methanol; F. GC 
injector. Atom labels for NMR assignments. 
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Figure 2. Microscale synthesis. (a) GC-MS chromatogram of reaction mixture from step E for 
sequence performed in the absence the benzophenone starting material; (b) GC-MS 
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chromatogram of reaction mixture from step E for clonazolam microscale synthesis; (c) EI 
mass spectrum for clonazolam peak (12.90 min) from microscale synthesis; (d) GC-MS 
chromatogram for clonazolam standard; (e). EI mass spectrum for clonazolam standard 
(12.90 min); (f) GC-MS chromatogram of reaction mixture from step E for nitrazolam 
microscale synthesis; (g) EI mass spectrum for nitrazolam peak (12.52 min) from microscale 
synthesis; (h) GC-MS chromatogram for nitrazolam standard; (i) EI mass spectrum for 
nitrazolam standard (12.51 min).  
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Figure 3 (a-c): Proposed EI mass spectral fragmentation pathways for nitrazolam and 
clonazolam. 
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Figure 4: Electrospray ionization product ion mass spectra (150 V in-source CID) for (a) 
nitrazolam and (b) clonazolam. 
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